A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer

Clinical trial NCT00813956 · COMPLETED

Trial details

NCT number: NCT00813956
Sponsor: Sanofi
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Triple Negative Breast Cancer

Start date: 2008-12-01
Primary completion: 2012-10-01
Enrollment: 80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.